Laboratory Corp. of America Holdings
Laboratory Corp. of America Holdings (LabCorp, ticker LH) is a large clinical diagnostics and healthcare services company providing laboratory testing, diagnostic information, and drug development services to hospitals, physicians and biopharma clients. With a market capitalisation of about $23.6bn, LabCorp earns revenue from fee-for-service testing, contracts with healthcare providers, and outsourced clinical trial services. Key investor considerations include steady structural demand for diagnostics from an ageing population and growing use of personalised medicine, balanced against sensitivity to reimbursement rates, regulatory change and competition. LabCorp’s results can be cyclical—volumes often fluctuate with public-health trends such as respiratory outbreaks—and capital allocation choices and acquisitions affect near-term profitability. Investors should review recent financials, margins, cash flow and valuation, and consider exposure to healthcare reimbursement risk. This information is educational only and not personal financial advice; investors should assess suitability and consult a professional before acting.
Why It's Moving
Labcorp Stock Draws Bullish Analyst Eyes with $315 Consensus Target Signaling 19% Upside Potential.
- Analysts project 19.6% upside with targets ranging $290-$342, showing strong agreement on growth ahead.
- 26 Buy or Strong Buy ratings dominate, zero Sell calls, highlighting robust confidence in Labcorp's trajectory.
- Forward P/E of 14.8x and implied 69.5% growth underscore expectations for accelerating earnings momentum.
Labcorp Stock Draws Bullish Analyst Eyes with $315 Consensus Target Signaling 19% Upside Potential.
- Analysts project 19.6% upside with targets ranging $290-$342, showing strong agreement on growth ahead.
- 26 Buy or Strong Buy ratings dominate, zero Sell calls, highlighting robust confidence in Labcorp's trajectory.
- Forward P/E of 14.8x and implied 69.5% growth underscore expectations for accelerating earnings momentum.
When is the next earnings date for Laboratory Corp. of America Holdings (LH)?
Laboratory Corporation of America Holdings (LH) next earnings release is typically expected in late April or early May, following its historical pattern of reporting Q1 results approximately 30-45 days after quarter-end. As of March 30, 2026, no specific date has been confirmed for the upcoming report covering Q1 2026. Investors should monitor official company announcements for the precise timing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Laboratory Corp. of America Holdings stock, expecting its value to rise.
Financial Health
Laboratory Corp. is performing well with solid profits, cash flow, and revenue generation.
Dividend
Laboratory Corp. of America Holdings has a low dividend yield of 1.14%, making it less attractive for dividend-focused investors. If you invested $1000 you would be paid $11.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LH
Riding The Regulatory Wave In Healthcare
The Department of Justice's investigation into UnitedHealth's Medicare billing practices has cast a shadow over the health insurance industry, potentially leading to stricter oversight. This creates an investment opportunity in companies that provide compliance and auditing services, which are essential for navigating a more complex regulatory environment.
Published: July 25, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics demand trends
Ageing populations and personalised medicine support long-term demand for testing, though volumes can fluctuate with public-health events and policy changes.
Global service footprint
A broad geographic presence and biopharma contracts diversify revenue, but differing regulations and reimbursement rules across markets add complexity.
Innovation and services
Investments in technology and clinical-trial services may improve margins over time, although competition and pricing pressure can constrain gains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Chemed Corp.
Provides hospice and palliative care services to patients facing life-limiting illness
Alignment Healthcare, Inc.
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale Senior Living Inc.
A leading owner and operator of senior living communities in the United States.
